Patients’ individual genomes may affect efficacy, safety of gene editing
Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people’s cells, and multiple trials are recruiting or in the planning stages. A new study led by Boston Children’s Hospital and the University of Montreal raises a note of caution, finding that person-to-person genetic differences may undercut the efficacy of the gene editing process or, in more rare cases, cause a potentially dangerous “off target” effect.
The study adds to evidence that gene editing may need to be adapted to each patient’s genome, to ensure there aren’t variants in DNA sequence in or near the gene being targeted that would throw off the technology. Findings appear this week in the Proceedings of the National Academy of Sciences Early Edition (December 11-15).
“Humans vary in their DNA sequences, and what is taken as the ‘normal’ DNA sequence for reference cannot account for all these differences,” says Stuart Orkin, MD, of Dana-Farber Boston Children’s Cancer and Blood Disorders Center and co-corresponding author on the study with Matthew Canver, an MD-PhD student at Harvard Medical School. “We recommend that common variation be taken into account in designing targeting systems for therapeutic editing, to maximize efficacy and minimize potential safety concerns.”
The study analyzed 7,444 previously published whole-genome sequences. Based on a list of about 30 disease-related DNA targets that researchers are interested in altering through gene editing, the researchers made a second list of nearly 3,000 guide RNAs (gRNAs). These are bits of genetic code that have been developed to direct CRISPR-Cas9 enzymes to the right editing location on or adjacent to the target, like the address on an envelope.
The team, led by Orkin, Canver and Samuel Lessard of the University of Montreal, then looked to see whether any of the 7,444 individuals carried DNA sequence variants (“letter changes” or insertions/deletions) in the areas the gRNAs are looking for.
“If there are genetic differences at the site that CRISPR reagents are targeting for therapy, you are at risk for decreased efficacy or treatment failure,” explains Canver, who conceived and led the study in Orkin’s Boston Children’s Hospital lab. “A difference in just a single base pair can cause a decrease in binding efficiency due to a mismatch with the guide RNA. Overall, this can cause a reduction in treatment efficacy.”
The team found that such occurrences in the genome are not uncommon; about 50 percent of the analyzed gRNAs had the potential to be affected by variants at their target sites. In a few cases, the team found genetic variants that cause DNA sequences in the genome to more closely match a gRNA that could potentially draw it to the wrong place — resulting in an edit of a gene or other DNA region that’s not meant to be targeted.
“In rare cases, there was the potential to create very potent ‘off-target’ sites – where CRISPR reagents could bind and cut where they’re not intended to,” says Canver. “If an off-target effect happens to be in, say, a tumor suppressor gene, that would be a big concern.”
Although the study looked at CRISPR-Cas9 gene editing, the researchers believe their findings extend to other gene-editing tools such as zinc-finger nucleases (ZFN) and TAL effector nucleases.
“The unifying theme is that all these technologies rely on identifying stretches of DNA bases very specifically,” says Canver. “So, a variant that affects the target sequence could reduce guide RNA binding. Variants can also lead to binding at new sites that could potentially cause harm. As these gene-editing therapies continue to develop and start to approach the clinic, it’s important to make sure each therapy is going to be tailored to the patient that’s going to be treated.”
The Latest on: Gene editing
- A New Clinical Trial Will Explore Gene Editing For Sickle Cell Diseaseon April 15, 2021 at 7:22 pm
Researchers will conduct a first-in-human clinical trial of a CRISPR gene correction therapy on people with severe sickle cell disease.
- An on-off switch for gene editingon April 14, 2021 at 12:50 pm
A new gene editing technology called CRISPRoff allows researchers to control gene expression with high specificity while leaving the sequence of the DNA unchanged.
- Silk moth's diapause reverts back to ancestors' through gene editingon April 13, 2021 at 10:33 am
Diapause is a phenomenon in which animals and insects foresee changes in the environment and actively reduce metabolism, or halt regular differentiation and development. It is an adaptation strategy ...
- A Massive New Gene Editing Project Is Out to Crush Alzheimer’son April 13, 2021 at 7:00 am
By studying iPSCs, we might be able to follow clues that lead to the genetic causes of Alzheimer’s and other dementias, paving the road for gene therapies.
- Gene Editing Market | 2021 Global Industry Analysis By Covid-19 Impact On Healthcare Sector, Business With Forecast To 2027on April 11, 2021 at 10:58 pm
Global ”Gene Editing Market“ 2020 industry research report gives Advancement strategies and plans are talked about just ...
- CRISPR-on, CRISPR-off: New game-changing gene editing technique is entirely reversibleon April 10, 2021 at 9:39 am
US researchers have unveiled a significant upgrade to the CRISPR gene editing system, which, unlike its predecessor, can target specific genes with high precision and make completely reversible ...
- Genetic Engineering 2.0: An On-Off Switch for Gene Editingon April 10, 2021 at 8:34 am
New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchanged. Over the past decade, the CRISPR-Cas9 gene editing system has revolutionized genetic ...
- PNA-based gene editing technique can advance gene discoveryon April 7, 2021 at 10:31 pm
In an article published in the April 8 issue of Nature, the National Institutes of Health's Somatic Cell Gene Editing Consortium provided a detailed update on the progress of their nationwide effort ...
- Bayer-backed Metagenomi bumps up series A to $75M as it gears up for gene editing pushon April 7, 2021 at 6:15 am
Metagenomi has added a cool $10 million extra to its January series A funding round with help from RA Capital as it also adds the VC firm’s M.D. to the board. Metagenomi got off a respectable $65 ...
- Japanese consumers more concerned about gene-editing of livestock than of vegetables, survey showson April 5, 2021 at 9:00 pm
Japanese consumers are more worried about the use of emerging gene-editing techniques such as CRISPR-Cas9 on livestock than they are about their use on plants, a survey has found. The presentation of ...
via Google News and Bing News